Abstract

Objective To observe the efficacy of intravitreal injection of ranibizumab (IVR) for retinal angiomatous proliferation (RAP).Methods Eleven patients (14 eyes) with RAP were enrolled in this retrospective clinical study.The best-corrected visual acuity (BCVA),central retinal thickness (CRT),and maximum retinal thickness (MRT) were detected by examination of visual acuity and optical coherence tomography (OCT).The average BCVA was 0.17 ± 0.21,CRT was (382.71 ± 219.07) μm,MRT was (746.36±268.29) μm.All eyes received 0.5 mg (0.05 ml) ranibizumab injection.Follow-up visits were performed monthly after injection.The mean follow-up time was (15.38 ± 13.64) month.Injections were repeated if the eyes with retinal edema.The mean number of repetitive IVR was (3.7 ± 1.0) times/eye (from 1 to 10 times).Changes in BCVA,CRT,MRT and complications were observed at the last follow up.Results At the last follow-up,the mean BCVA was 0.28±0.26 (from 0.01 to 1.0).Of 14 eyes,visual acuity improved in 11 eyes,not changed in 2 eyes and decreased in 1 eye.The difference of BCVA was significant between before and after the treatment (t =3.167,P =0.007).The mean CRT was (166.14 ±52.79) μm,which was less than that of pre-treatment values (t=3.737,P=0.002).The mean MRT was (360.43±102.19) μm,which was less than that of pre-treatment values (t=6.106,P=0.000).No ocular or systemic adverse effects occurred.Conclusion IVR is an efficient and safe treatment for RAP,with visual acuity improvement,decrease of CRT and MRT. Key words: Retinal diseases/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal/therapeutic use

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call